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Summary
Background A third of transient ischaemic attacks (TIAs) and ischaemic strokes are of undetermined cause (ie, 
cryptogenic), potentially undermining secondary prevention. If these events are due to occult atheroma, the risk-
factor proﬁ le and coronary prognosis should resemble that of overt large artery events. If they have a cardioembolic 
cause, the risk of future cardioembolic events should be increased. We aimed to assess the burden, outcome, risk 
factors, and long-term prognosis of cryptogenic TIA and stroke.
Methods In a population-based study in Oxfordshire, UK, among patients with a ﬁ rst TIA or ischaemic stroke from 
April 1, 2002, to March 31, 2014, we compared cryptogenic events versus other causative subtypes according to the 
TOAST classiﬁ cation. We compared markers of atherosclerosis (ie, risk factors, coronary and peripheral arterial disease, 
asymptomatic carotid stenosis, and 10-year risk of acute coronary events) and of cardioembolism (ie, risk of cardioembolic 
stroke, systemic emboli, and new atrial ﬁ brillation [AF] during follow-up, and minor-risk echocardiographic 
abnormalities and subclinical paroxysmal AF at baseline in patients with index events between 2010 and 2014). 
Findings Among 2555 patients, 812 (32%) had cryptogenic events (incidence of cryptogenic stroke 0·36 per 
1000 population per year, 95% CI 0·23–0·49). Death or dependency at 6 months was similar after cryptogenic stroke 
compared with non-cardioembolic stroke (23% vs 27% for large artery and small vessel subtypes combined; p=0·26) 
as was the 10-year risk of recurrence (32% vs 27%; p=0·91). However, the cryptogenic group had fewer atherosclerotic 
risk factors than the large artery disease (p<0·0001), small vessel disease (p=0·001), and cardioembolic (p=0·008) 
groups. Compared with patients with large artery events, those with cryptogenic events had less hypertension 
(adjusted odds ratio [OR] 0·41, 95% CI 0·30–0·56; p<0·0001), diabetes (0·62, 0·43–0·90; p=0·01), peripheral vascular 
disease (0·27, 0·17–0·45; p<0·0001), hypercholesterolaemia (0·53, 0·40–0·70; p<0·0001), and history of smoking 
(0·68, 0·51–0·92; p=0·01), and compared with small vessel and cardioembolic subtypes, they had no excess risk of 
asymptomatic carotid disease (adjusted OR 0·64, 95% CI 0·37–1·11; p=0·11) or acute coronary events (adjusted 
hazard ratio [HR] 0·76, 95% CI 0·49–1·18; p=0·22) during follow-up. Compared with large artery and small vessel 
subtypes combined, patients with cryptogenic events also had no excess of minor-risk echocardiographic abnormalities 
(cryptogenic 37% vs 45%; p=0·18) or paroxysmal AF (6% vs 10%; p=0·17) at baseline or of new AF (adjusted HR 1·23, 
0·78–1·95; p=0·37) or presumed cardioembolic events (1·16, 0·62–2·17; p=0·64) during follow-up.
Interpretation The clinical burden of cryptogenic TIA and stroke is substantial. Although stroke recurrence rates are 
comparable with other subtypes, cryptogenic events have the fewest atherosclerotic markers and no excess of 
cardioembolic markers.
Funding Wellcome Trust, Wolfson Foundation, UK Stroke Association, British Heart Foundation, Dunhill Medical Trust, 
National Institute for Health Research, Medical Research Council, and the NIHR Oxford Biomedical Research Centre. 
Copyright © Li et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
By contrast with coronary and peripheral vascular events, 
up to a third of transient ischaemic attacks (TIAs) or 
ischaemic strokes—about 400 000 cases annually in 
western Europe—are of undetermined cause (ie, 
cryptogenic).1 In young patients, half of strokes are 
cryptogenic.1 Yet, recurrence rates after cryptogenic TIA 
and ischaemic stroke are close to those of large artery and 
cardioembolic causes.2 The Cryptogenic Stroke/ESUS 
International Working Group proposed that cryptogenic 
events might often be caused by occult arterial sources of 
thromboembolism, paroxysmal atrial ﬁ brillation (AF), 
patent foramen ovale (PFO), or minor-risk cardiac 
structural abnormalities.3–5
However, even with detailed investigation, only a third 
of patients with cryptogenic stroke have aortic atheroma 
or potentially unstable plaques in other vessels, some of 
which are probably coincidential.3,6 Similarly, although 
long-term monitoring of heart rhythm identiﬁ es 
paroxysmal AF in up to a third of patients with 
cryptogenic events,7,8 the relevance of these mostly short 
episodes of AF for cryptogenic stroke is uncertain.
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Findings from the INTERSTROKE study9 suggested 
that traditional risk factors account for 90% of the risk of 
all stroke, but the investigators did not diﬀ erentiate 
between stroke subtypes, and risk-factor proﬁ les seem 
to diﬀ er across ischaemic stroke subtypes.10,11 Since 
atheroma is a systemic disease with known risk factors, if 
occult or non-stenotic atheroma was the underlying 
cause of cryptogenic events, the atherosclerotic risk-
factor proﬁ le and the extent of atherosclerosis in other 
vascular beds should be closer to that of overt large artery 
TIA or stroke and the risk of coronary events during 
follow-up should be high, particularly because plaque 
instability is also a systemic phenomenon.12 Similarly, if 
paroxysmal AF was the underlying cause of cryptogenic 
events, the long-term risk of new AF would be increased, 
and if covert cardioembolism from other sources was 
responsible, the risk of future overtly embolic events (ie, 
with an identiﬁ ed embolic source) would be increased.13,14
Most previous studies of risk factors or prognosis of 
cryptogenic stroke were hospital based (appendix p 2), 
did not separate cryptogenic cases from cases with more 
than one cause or from cases with unknown cause 
because of incomplete investigation (appendix p 4), and 
rarely compared crypto genic stroke speciﬁ cally with other 
stroke subtypes.15,16 Also, no study has reported the 
coronary prognosis or risk of cardioembolic events by 
subtypes, and no study has included a follow-up of 
10 years to detect any late increase in new AF or 
cardioembolism.  Therefore, we assessed the risk-factor 
proﬁ le, prevalence of atherosclerotic and cardioembolic 
markers, outcome, and long-term prognosis of ischaemic 
stroke subtypes in a large population-based study of TIA 
and stroke.
Methods
Study design and participants
The Oxford Vascular Study (OXVASC) is an ongoing 
population-based study of the incidence and outcome of 
all acute vascular events.17 The study population 
comprises all 92 728 individuals, irrespective of age, who 
are registered with 100 general practitioners in nine 
general practices in Oxfordshire, UK. The analysis 
reported herein includes consecutive cases with a ﬁ rst 
TIA or ischaemic stroke from April 1, 2002, to March 31, 
2014, with follow-up until Sept 30, 2014.
The OXVASC study design has been described in 
detail elsewhere.17 Brieﬂ y, several overlapping methods 
of hot and cold pursuit were used to achieve near-
complete ascertainment of all individuals with TIA or 
stroke.17,18 These included (1) a daily, rapid-access TIA 
and stroke clinic to which participating general 
practitioners and the local emergency department team 
referred individuals with suspected TIA or minor 
stroke; (2) daily searches of admissions to medical, 
stroke, neurology, and other relevant wards; (3) daily 
searches of the local emergency department attendance 
Research in context
Evidence before this study
We searched PubMed for articles on cryptogenic transient 
ischaemic attack (TIA) or cryptogenic stroke published 
between Jan 1, 1993, and Feb 1, 2015, with the search terms 
“cryptogenic stroke”, “undetermined stroke”, “stroke of 
undetermined aetiology”, and “embolic strokes of 
undetermined source”. We also identiﬁ ed all hospital-based 
and population-based stroke studies that reported data on 
the frequency of vascular risk factors or prognosis according 
to the Trial of Org 10172 in Acute Stroke Treatment 
classiﬁ cation, or similar, with the search terms “stroke and 
incidence”, “stroke and population-based study”, “stroke and 
hospital-based study”, “stroke and community-based study”, 
“stroke and risk factors”, “stroke subtype”, and ” stroke 
classiﬁ cation”. Others have suggested that cryptogenic TIA or 
stroke might often be caused by occult cardiac or arterial 
sources of thromboembolism. However, most previous 
studies of risk factors or prognosis of cryptogenic stroke were 
hospital based, did not separate cryptogenic cases with 
detailed diagnostic work-up from cases with more than one 
cause or cases with unknown cause because of incomplete 
investigation, and rarely compared cryptogenic stroke with 
other subtypes, and no study reported the long-term 
coronary prognosis or risk of cardioembolic events by 
causative subtypes.
Added value of this study
In this large population-based study of TIA and ischaemic stroke 
with long-term follow-up, we conﬁ rmed that the incidence of 
cryptogenic events was high and the risk of recurrent stroke was 
substantial. However, patients with cryptogenic events had the 
lowest prevalence of risk factors for atherosclerosis, the lowest 
frequency of comorbid atherosclerotic disease, and the lowest 
risk of acute coronary events compared with patients with 
events of known cause. Similarly, patients with cryptogenic 
events had low long-term risk of new atrial ﬁ brillation (AF), low 
risk of recurrent cardioembolic stroke or systemic embolism, and 
no excess prevalence of paroxysmal AF or minor-risk cardiac 
abnormalities on baseline investigation.
Implications of all the available evidence
In view of the large burden of cryptogenic TIA and ischaemic 
stroke, further research on potential causes and treatments is 
needed. More research on detection of aortic plaque and other 
non-stenosing atherosclerosis and on intensive cardiac rhythm 
monitoring and detection of patent foramen ovale in older 
patients may be informative, but possible causal links with 
cryptogenic stroke should be interpreted with caution. However, 
in view of the high rate of recurrent cryptogenic stroke, 
randomised trials of available preventive treatments, such as new 
anticoagulants, are justiﬁ ed despite uncertainty about cause. 
See Online for appendix
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register; (4) daily searches of in-hospital death records 
via the bereavement oﬃ  ce; (5) monthly searches of all 
death certiﬁ cates and coroner’s reports for out-of-
hospital deaths; (6) monthly searches of general 
practitioner diagnostic coding and hospital discharge 
codes; and (7) monthly searches of all brain and vascular 
imaging referrals.
Patients gave written informed consent after an event 
or assent was obtained from a relative for patients who 
were unable to provide consent. OXVASC was approved 
by the local research ethics committee.
Procedures
We collected demographic data, atherosclerotic risk 
factors (ie, male sex, previous hypertension, previous 
diabetes, history of smoking, and previous hyper-
cholesterolaemia), and history of coronary or peripheral 
vascular disease during face-to-face interviews and cross-
referenced these data with primary care records. For 
patient data ascertained after death, medical records 
were used. Patients routinely had 12-lead 
electrocardiography (ECG) and routine bloods (ie, full 
blood count, clotting, C-reactive protein, erythrocyte 
sedimentation rate, liver function, renal function, thyroid 
function, electrolytes, and lipid proﬁ le) after the event. 
Thrombophilia screening, vasculitis screening, and 
genetic tests, where appropriate, were done for patients 
with cryptogenic TIA or stroke or those younger than 
55 years. During the 12-year study period of OXVASC, 
diﬀ erent imaging protocols were used in two diﬀ erent 
time periods. From April 1, 2002, to March 31, 2010 
(phase 1), CT brain and carotid doppler were the ﬁ rst-line 
imaging methods, with MRI or magnetic resonance 
angiography done in selected patients when clinically 
indicated. Echo cardiography, 24-h ECG (Holter monitor), 
and 5-day ambulatory home ECG monitoring (R test) 
were also done when clinically indicated. From April 1, 
2010, to March 31, 2014 (phase 2), brain MRI and 
magnetic resonance angiography of extracranial and 
intracranial vessels became the ﬁ rst-line imaging 
methods, and all clinic patients had R tests and 
transthoracic echocardiography. We also referred patients 
for screening for PFO to the Department of Cardiology at 
John Radcliﬀ e Hospital (Oxford, UK) when clinically 
indicated (ie, patients aged <55 years, those with 
concomitant venous thrombosis, those who went on a 
long-haul ﬂ ight preceding the cerebrovascular event, or 
those with clinical or imaging evidence of multi-territory 
events with undetermined cause).
All cases were reviewed by a senior neurologist (PMR) 
and the cause of stroke was classiﬁ ed according to the 
modiﬁ ed Trial of Org 10172 in Acute Stroke Treatment 
(TOAST) criteria (appendix p 5).19 In view of the potential 
for bias, risk factors such as hypertension and diabetes 
were not included in the criteria.20 We classiﬁ ed patients 
in phase 1 as cryptogenic only if the diagnostic work-up 
included at least brain imaging, ECG, and extracranial 
imaging, and no clear cause was found. We classiﬁ ed 
patients with missing investigation as having unknown 
events, whereas events with more than one cause were 
classiﬁ ed separately. In phase 2, we extended the 
diagnostic work-up to include intracranial vascular 
imaging, R test, and echocardiography and used these 
additional results as indications for classiﬁ cation as listed 
in the appendix (p 5). We further classiﬁ ed all cryptogenic 
TIAs or strokes according to the embolic strokes of 
undetermined source (ESUS) criteria (appendix p 6).3
Patients were followed up face to face at 1, 6, 12, 60, and 
120 months by a study nurse or physician to identify 
recurrent strokes; acute coronary events and sudden 
cardiac deaths; any new AF; acute cardioembolic events, 
including recurrent cardioembolic stroke, acute embolic 
limb ischaemia, and visceral embolisation; and disability 
(modiﬁ ed Rankin Scale >2). Patients who had moved out 
of the study area were followed up via telephone at the 
same timepoints as face-to-face follow-up. We recorded 
all deaths during follow-up and their causes. All recurrent 
strokes and cardiac and peripheral vascular events that 
occurred during follow-up would also be identiﬁ ed by 
our ongoing daily case ascertainment. If a recurrent 
vascular event was suspected, the patient was reassessed 
and investigated by a study physician.
Statistical analysis
We calculated sex-speciﬁ c rates (per 1000 population per 
year) of incident stroke of cryptogenic cause in 10-year 
age bands and estimated 95% CIs assuming a Poisson 
distribution, standardised to the 2012 population of 
England and Wales. Recurrent strokes that were crypto-
genic in patients with a previous non-cryptogenic stroke 
were not included in our analyses of incident stroke.
We compared the frequency of atherosclerotic risk 
factors and of comorbid atherosclerotic disease (ie, 
history of coronary disease, peripheral vascular disease, 
and asymptomatic carotid stenosis) in each stroke 
subtype using the χ² test and logistic regression analysis 
adjusted for age and sex. We also did sensitivity analyses 
excluding all TIA events. At baseline, we compared the 
frequency of minor-risk echocardiographic abnormalities 
and subclinical paroxysmal AF on R test in cryptogenic 
cases versus large artery and small vessel subtypes in 
patients from phase 2 of the study using the χ² test.
We used Kaplan-Meier survival analysis to calculate 
the 1-year, 5-year, and 10-year actuarial risks of events 
during follow-up, censored at death or Sept 30, 2014, for 
each subtype and compared risks by Cox regression 
analysis adjusted for age and sex. We studied the 
following outcomes during follow-up: death, vascular 
death, ﬁ rst recurrent stroke, ﬁ rst recurrent ischaemic 
stroke, ﬁ rst acute coronary event, ﬁ rst cardioembolic 
event, and any new AF.
Because of the potential eﬀ ect of the change of 
investigation protocol in OXVASC in 2010 on the 
classiﬁ cation of cryptogenic TIA and stroke, we stratiﬁ ed 
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Cryptogenic 
(n=812)
Cardioembolic 
(n=668)
Large artery 
disease 
(n=280)
Small vessel 
disease (n=317)
Unknown 
cause (n=331)
More than 
one cause 
(n=90)
Other causes 
(n=57)
Total (n=2555) p value*
Baseline characteristics
Age (years) 70·4 (12·8) 77·9 (11·9) 73·3 (10·3) 69·7 (12·6) 81·2 (10·4) 77·2 (10·5) 56·7 (17·7) 73·9 (13·0) <0·0001
Sex
Male 402 (50%) 306 (46%) 172 (61%) 182 (57%) 112 (34%) 56 (62%) 32 (56%) 1262 (49%) <0·0001
Female 410 (50%) 362 (54%) 108 (39%) 135 (43%) 219 (66%) 34 (38%) 25 (44%) 1293 (51%) ··
Hypertension 432 (53%) 477 (71%) 208 (74%) 188 (59%) 203 (61%) 66 (73%) 26 (46%) 1600 (63%) <0·0001
Diabetes 99 (12%) 81 (12%) 52 (19%) 51 (16%) 55 (17%) 17 (19%) 2 (4%) 357 (14%) 0·004
Myocardial infarction 67 (8%) 117 (18%) 39 (14%) 16 (5%) 34 (10%) 18 (20%) 5 (9%) 296 (12%) <0·0001
Peripheral vascular disease† 31 (4%) 58 (9%) 40 (14%) 15 (5%) 27 (8%) 16 (18%) 3 (5%) 190 (7%) <0·0001
Hypercholesterolaemia 265 (33%) 240 (36%) 137 (49%) 105 (33%) 100 (30%) 37 (41%) 18 (32%) 902 (35%) <0·0001
Smoking status
Present‡ 127 (16%) 45 (7%) 54 (19%) 77 (24%) 30 (9%) 17 (19%) 11 (19%) 361 (14%) <0·0001
Past§ 317 (39%) 302 (45%) 129 (46%) 120 (38%) 120 (37%) 42 (47%) 25 (44%) 1055 (41%) 0·02
Secondary prevention during follow-up
On antiplatelets
At 1 month¶ 764/809 (94%) 331/555 (60%) 258/273 (95%) 306/317 (97%) 196/244 (80%) 59/86 (69%) 47/55 (86%) 1961/2339 (84%) <0·0001
At 1 year|| 711/766 (93%) 186/435 (43%) 228/247 (92%) 290/310 (94%) 110/151 (73%) 38/76 (50%) 40/46 (87%) 1603/2031 (79%) <0·0001
On anticoagulants
At 1 month¶ 9/809 (1%) 221/555 (40%) 12/273 (4%) 2/317 (1%) 19/244 (8%) 27/86 (31%) 8/55 (15%) 298/2339 (13%) <0·0001
At 1 year|| 11/766 (1%) 239/435 (55%) 11/247 (4%) 2/310 (1%) 2/151 (1%) 36/76 (47%) 4/46 (9%) 305/2031 (15%) <0·0001
On a statin
At 1 month¶ 650/809 (80%) 379/555 (68%) 232/273 (85%) 266/317 (84%) 132/244 (54%) 65/86 (76%) 31/55 (56%) 1755/2339 (75%) <0·0001
At 1 year|| 627/766 (82%) 315/435 (72%) 221/247 (89%) 256/310 (83%) 80/151 (53%) 61/76 (80%) 29/46 (63%) 1589/2031 (78%) <0·0001
On one or more antihypertensives
At 1 month¶ 590/809 (73%) 445/555 (80%) 224/273 (82%) 258/317 (81%) 150/244 (61%) 72/86 (84%) 32/55 (58%) 1771/2339 (76%) <0·0001
At 1 year|| 574/766 (75%) 358/435 (82%) 213/247 (86%) 246/310 (79%) 89/151 (59%) 65/76 (86%) 27/46 (59%) 1572/2031 (77%) <0·0001
Data are mean (SD), number (%), or n/N (%). *For heterogeneity among all subtypes (χ² test for categorical variables and one-way ANOVA test for continuous variables). †Data missing for one patient with event 
of unknown cause. ‡Data missing for eight patients: four with cardioembolic events, three with events of unknown cause, and one with a cryptogenic event. §Data missing for nine patients: four with 
cardioembolic events, three with events of unknown cause, and two with cryptogenic events. ¶Data available for 2339 patients; 216 died before 1 month of follow-up. ||Data available for 2031 patients: 470 died 
before 1 year of follow-up, 45 have not reached 1-year follow-up, and nine had missing data.
Table 1: Baseline characteristics and secondary prevention during follow-up among transient ischaemic attack or ischaemic stroke subtypes 
Cryptogenic 
(n=812)
LAD 
(n=280)
Cryptogenic vs LAD Non-LAD 
(n=985)
Cryptogenic vs non-LAD
Crude OR 
(95% CI)
p value Age and sex 
adjusted OR 
(95%CI)
p value Crude OR 
(95% CI)
p value Age and sex 
adjusted OR 
(95% CI)
p value
Age (years) 70·4
(12·8)
73·3
(10·3)
0·98
(0·97–0·99)
0·001 0·98
(0·97–0·99)
0·0001 75·3
(12·7)
0·97
(0·96–0·98)
<0·0001 0·97
(0·96–0·98)
<0·0001
Male 402
(50%)
172
(61%)
0·62
(0·47–0·81)
0·001 0·57
(0·43–0·75)
0·0001 488
(50%)
1·00
(0·83–1·20)
0·99 0·85
(0·70–1·03)
0·09
Hypertension 432
(53%)
208
(74%)
0·39
(0·29–0·53)
<0·0001 0·41
(0·30–0·56)
<0·0001 665
(68%)
0·55
(0·45–0·66)
<0·0001 0·64
(0·53–0·79)
<0·0001
Diabetes 99
(12%)
52
(19%)
0·61
(0·42–0·88)
0·008 0·62
(0·43–0·90)
0·01 132
(13%)
0·90
(0·68–1·19)
0·45 0·89
(0·67–1·18)
0·40
Hypercholesterolaemia 265
(33%)
137
(49%)
0·51
(0·38–0·67)
<0·0001 0·53
(0·40–0·70)
<0·0001 345
(35%)
0·90
(0·74–1·09)
0·29 0·91
(0·74–1·10)
0·34
Past or present smoker* 444 
(55%)
183
(65%)
0·64
(0·49–0·85)
0·002 0·68
(0·51–0·92)
0·01 544
(55%)
0·98
(0·81–1·18)
0·79 0·92
(0·76–1·13)
0·43
Data are mean (SD) or number (%), unless otherwise speciﬁ ed. LAD=large artery disease. Non-LAD=small vessel disease and cardioembolic events combined. OR=odds ratio. *Data missing for four patients with 
cardioembolic events and two with cryptogenic events.
Table 2: Prevalence of diﬀ erent risk factors in cryptogenic versus other transient ischaemic attack and ischaemic stroke subtypes 
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analyses by phase (phase 1 vs phase 2). We also did a 
sensitivity analysis conﬁ ned to an ideal cryptogenic 
group using the ESUS deﬁ nition; this group included all 
patients with cryptogenic events who had brain imaging, 
intracranial and extracranial vascular imaging, prolonged 
cardiac monitoring (5 days), and echocardiography. All 
analyses were done using SPSS version 20.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, writing of the report, or 
the decision to submit for publication. All authors had 
full access to all the data in the study, and the 
corresponding author had ﬁ nal responsibility for the 
decision to submit for publication.
Figure 1: Number of atherosclerotic risk factors and frequency of comorbid atherosclerotic disease in diﬀ erent transient ischaemic attack and ischaemic 
stroke subtypes
Frequencies of risk factors and comorbid disease are shown (A) overall and for (B) females and (C) males. Data on smoking status were missing in four patients with 
cardioembolic events and two patients with cryptogenic events. Risk factors were male sex, hypertension, diabetes, hypercholesterolaemia, and history of smoking. 
Male sex was not taken into account in the stratiﬁ cation analysis by sex (ie, B and C). p values are for heterogeneity among all subtypes using the χ² test. 
ESUS=embolic strokes of undetermined source. LAD=large artery disease. PVD=peripheral vascular disease. SVD=small vessel disease. *Asymptomatic carotid stenosis 
≥50% at bifurcation. 
Number of atherosclerotic risk factors Comorbid atherosclerotic disease
 
Overall
0
20
40
60
80
100
Large artery
disease
(n=172)
Small vessel
disease
(n=182)
Cardioembolic
(n=306)
Cryptogenic
(n=402)
ESUS
(n=100)
Fr
eq
ue
nc
y 
(%
)
0
20
40
60
80
100
Fr
eq
ue
nc
y 
(%
)
(n=108) (n=135) (n=358) (n=408) (n=89)
0
20
40
60
80
100
(n=280) (n=317) (n=664) (n=810) (n=189)
Fr
eq
ue
nc
y 
(%
)
Fr
eq
ue
nc
y 
(%
)
Fr
eq
ue
nc
y 
(%
)
Fr
eq
ue
nc
y 
(%
)
Event subtypes
0
10
20
30
p<0·0001 p<0·0001 p<0·0001
0
10
20
30
Myocardial infarction PVD Asymptomatic
carotid disease*
p<0·0001 p=0·0004 p<0·0001
0
10
20
30
Comorbid disease
p<0·0001 p<0·0001 p<0·0001
 
 
p<0·0001
 
A
Females
p<0·0001
B
Males
p<0·0001
C
≥3 2 1 0 LAD Cardioembolic SVD Cryptogenic ESUS
Articles
908 www.thelancet.com/neurology   Vol 14   September 2015
Results
Of 2555 patients with a ﬁ rst ischaemic event (1607 stroke 
and 948 TIA), 812 (32%) were classiﬁ ed as cryptogenic, 
668 (26%) cardioembolic, 280 (11%) large artery disease, 
317 (12%) small vessel disease, 331 (13%) unknown cause, 
90 (4%) with more than one cause, and 57 (2%) as other 
causes. These proportions were in line with data from 
other published population-based studies in pre-
dominantly white populations (appendix p 7). Among the 
226 patients aged younger than 55 years, 108 (48%) had 
cryptogenic events. Incidence of cryptogenic stroke was 
0·36 per 1000 population per year (95% CI 0·23–0·49) 
and seemed to be higher in men than women, particularly 
at younger ages (ie, <55 years; appendix p 8). 
Table 1 lists the baseline characteristics of all patients. 
Among 2441 patients who presented with cerebral events 
(ie, excluding ocular ischaemic events), 2315 (95%) had 
brain imaging or autopsy for the index event. The 
appendix (p 9) details the diagnostic work-up in patients 
classiﬁ ed as having cryptogenic events. All patients were 
prescribed standard treatment after the event, and 
secondary prevention during follow-up was broadly 
similar between patients with cryptogenic events and 
those with events of known cause (table 1). 
Patients with cryptogenic events had the lowest 
prevalence of risk factors for atherosclerosis (table 2). 
Compared with patients with large artery TIA or stroke, 
they had less hypertension (age-adjusted and sex-adjusted 
odds ratio [OR] 0·41, 0·30–0·56; p<0·0001), diabetes 
(0·62, 0·43–0·90; p=0·01), hyper cholestero laemia (0·53, 
0·40–0·70; p<0·0001), and history of smoking (0·68, 
0·51–0·92; p=0·01). Moreover, no individual risk factor 
was proportionally more prevalent in the cryptogenic 
than in the non-large artery disease groups (ie, 
cardioembolic and small vessel disease; table 2) and the 
cryptogenic group had fewer risk factors overall (ﬁ gure 1) 
than the large artery disease (p<0·0001), small vessel 
disease (p=0·001), and cardioembolic (p=0·008) groups, 
with similar ﬁ ndings for the ESUS-deﬁ ned cryptogenic 
group (p<0·0001, p=0·0003, and p=0·001, respectively; 
ﬁ gure 1). The results were broadly similar for men and 
women (ﬁ gure 1), analyses that excluded TIA (appendix 
p 10), OXVASC phase 1 and phase 2 (appendix p 11), 
analyses that included only patients with MRI or only 
patients with acute infarct on imaging (appendix p 12), 
and ESUS versus large artery disease subtype and ESUS 
versus non-large artery disease subtypes (appendix p 13). 
Compared with large artery and cardioembolic events, 
patients with cryptogenic events had the lowest 
prevalence of previous myocardial infarction and 
peripheral vascular disease (ﬁ gure 1). Compared with 
patients with large artery TIA or stroke, they had less 
peripheral vascular disease (40 [14%] vs 31 [4%]; adjusted 
OR 0·27, 0·17–0·45; p<0·0001), and weak evidence of 
less myocardial infarction (39 [14%] vs 67 [8%]; 0·68, 
0·44–1·04; p=0·08). Compared with patients with non-
large artery subtypes, those with cryptogenic events had 
less peripheral vascular disease (73 [7%] vs 31 [4%]; 
adjusted OR  0·56, 95% CI 0·36−0·87; p=0·01) and less 
myocardial infarction (133 [14%] vs 67 [8%]; 0·68, 
0·49−0·93; p=0·02). 
The cryptogenic group also had the least stenosis at the 
asymptomatic carotid bifurcation (ﬁ gure 2). They had no 
excess risk compared with small vessel and cardioembolic 
subtypes combined (adjusted OR 0·64, 95% CI 
0·37−1·11; p=0·11). 22 (3%) of 812 patients in the 
cryptogenic group had at least 50% asymptomatic 
stenosis, compared with 69 (25%) of 277 in the large 
artery disease group (adjusted OR 0·09, 95% CI 
0·06–0·16; p<0·0001), 23 (6%) of 390 in the cardioembolic 
group (0·58, 0·32–1·06; p=0·08), and ten (3%) of 302 in 
the small vessel disease group (0·82, 0·38–1·76; p=0·61). 
Results were similar in sensitivity analyses that excluded 
patients with TIA (appendix p 10), that were stratiﬁ ed by 
diﬀ erent study phases (appendix p 11), that included only 
cases with MRI (appendix p 12), and that compared the 
ESUS group with other subtypes (appendix p 13).
The cryptogenic group excluded all patients who were 
known to have or found to be in AF at initial assessment 
or during routine inpatient investigation. In phase 2 of 
the study, patients with TIA and non-disabling stroke 
had ambulatory home cardiac monitoring. The cause 
was changed to cardioembolic from cryptogenic or to 
more than one cause from large artery or small vessel 
subtypes if paroxysmal AF longer than 30 s was detected 
on ambulatory monitoring. Among the 322 (80%) of 
401 phase 2 patients with TIA or non-disabling stroke 
who had ambulatory monitoring—all of whom also had 
echocardiography—11 (6%) of 197 patients with 
cryptogenic events had paroxysmal AF longer than 30 s 
compared with 12 (10%) of 125 patients with other non-
cardioembolic events (ie, large artery disease and small 
vessel disease combined; p=0·17). The proportion of 
patients with minor-risk potential cardioembolic sources 
on echocardiography was 74 (37%) of 198 after cryptogenic 
Figure 2: Severity of stenosis at the asymptomatic carotid bifurcation in diﬀ erent transient ischaemic attack 
and ischaemic stroke subtypes
Carotid events were calculated as carotid stenosis (%) at the asymptomatic side; posterior circulation events were 
calculated as mean carotid stenosis (%) of both carotid arteries at the bifurcation. p values are for the diﬀ erence of 
stenosis distribution between cryptogenic and other subtypes.
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events and 57 (45%) of 127 after non-cardioembolic 
events (p=0·18). 
During 10 698 patient-years of follow-up, 1101 deaths, 
412 recurrent ischaemic strokes, 143 acute coronary 
events, and 26 acute peripheral events of presumed 
cardioembolic cause occurred. Among the 438 recurrent 
ischaemic strokes and acute peripheral vascular events, 
189 were presumed cardioembolic, of which 173 were AF 
related, with AF newly diagnosed during follow-up in 
39 of these patients. A further 53 patients also developed 
new AF during follow-up, but had no embolic event.
Compared with patients with non-cardioembolic 
ischaemic stroke (ie, small vessel disease and large artery 
disease stroke), a similar proportion of those with 
cryptogenic stroke died or were dependent (modiﬁ ed 
Rankin Scale >2) at 6 months (cryptogenic 23% vs 27%; 
p=0·26). Moreover, between cryptogenic stroke and non-
cardioembolic ischaemic stroke, the 10-year risks of 
death (46% vs 49%; p=0·63), vascular death (15% vs 15%; 
p=0·68), or any recurrent stroke (32% vs 27%; p=0·91) 
were also comparable (table 3). Risks of recurrent 
ischaemic stroke did not diﬀ er signiﬁ cantly between 
stroke subtypes (table 3; ﬁ gure 3). However, when index 
TIAs were included in the analysis, cryptogenic cases 
had a lower risk of recurrent ischaemic stroke than did 
cases with cardioembolic cause (age-adjusted and sex-
adjusted hazard ratio [HR] 0·66, 95% CI 0·51–0·87; 
p=0·003), large artery disease (0·67, 0·48–0·92; p=0·02), 
and small vessel disease (0·67, 0·49–0·91; p=0·01); 
however, this diﬀ erence between cryptogenic cases and 
cases with known cause was mainly due to lower early 
risks (<90 days) of recurrent ischaemic stroke after 
cryptogenic events than after events of known cause 
(adjusted HR 0·47, 95% CI 0·32–0·70; p=0·0001). The 
risks of ischaemic stroke after 90 days were not 
signiﬁ cantly lower after cryptogenic events than after 
cases of known cause (adjusted HR 0·80, 95% CI 
0·60–1·06; p=0·12). 70 (63%) of 112 recurrent strokes 
after cryptogenic events remained cryptogenic after 
further investigation (table 4).
Cryptogenic (n=392) Small vessel disease (n=220) Large artery disease (n=158) Cardioembolic (n=472) p value
Number % (95% CI)* Number % (95% CI)* Number % (95% CI)* Number % (95% CI)*
Disability (mRS >2)
Premorbid† 58 15%‡ 18 8%‡ 17 11%‡ 146 32%‡ p<0·0001§
6 months¶ 89 23%‡ 50 23%‡ 51 32%‡ 305 66%‡ p<0·0001§
Mortality
1 year 23 6·0% (3·6–8·4) 2 0·9% (0·0–2·1) 23 14·7% (9·2–20·2) 196 41·7% (37·2–46·2) p<0·0001
5 years 80 24·9% (20·0–29·8) 37 19·8% (13·9–25·7) 42 30·9% (22·9–38·9) 280 64·6% (59·9–69·3) p<0·0001
10 years 114 45·5% (38·4–52·6) 64 44·9% (35·9–53·9) 56 54·9% (42·6–67·2) 317 83·3% (78·2–88·4) p<0·0001
Vascular death
1 year 11 2·8% (1·2–4·4) 2 0·9% (0·0–2·1) 12 7·8% (3·5–12·1) 155 34·0% (29·7–38·3) p<0·0001
5 years 32 10·0% (6·7–13·3) 12 6·4% (2·9–9·9) 14 9·9% (4·8–15·0) 183 43·5% (38·6–48·4) p<0·0001
10 years 39 15·4% (10·3–20·5) 17 12·2% (6·1–18·3) 18 21·7% (8·6–34·8) 195 53·4% (46·5–60·3) p<0·0001
Any recurrent stroke
1 year 35 9·1% (6·2–12·0) 27 12·3% (8·0–16·6) 21 14·0% (8·5–19·5) 54 15·1% (11·4–18·8) 0·11
5 years 76 24·0% (19·1–28·9) 41 20·5% (14·8–26·2) 31 24·1% (16·3–31·9) 79 27·8% (21·9–33·7) 0·25
10 years 85 31·9% (25·2–38·6) 47 26·9% (19·5–34·3) 32 26·9% (17·7–36·1) 87 40·0% (30·6–49·4) 0·13
Any recurrent ischaemic stroke
1 year 34 8·8% (6·1–11·5) 27 12·3% (8·0–16·6) 20 13·4% (7·9–18·9) 50 14·0% (10·3–17·7) 0·19
5 years 73 23·2% (18·3–28·1) 40 20·0% (14·3–25·7) 30 23·4% (15·8–31·0) 72 25·3% (19·6–31·0) 0·49
10 years 79 28·6% (22·3–34·9) 46 26·4% (19·1–33·7) 31 26·2% (17·0–35·4) 79 36·3% (26·9–45·7) 0·32
Any acute coronary syndrome
1 year 5 1·3% (0·1–2·5) 0 ·· 6 4·1% (1·0–7·2) 12 3·3% (1·3–5·3) 0·008
5 years 14 4·2% (2·0–6·4) 9 4·6% (1·7–7·5) 11 9·5% (4·0–15·0) 20 8·2% (4·5–11·9) 0·10
10 years 18 8·7% (3·6–13·8) 11 7·3% (2·6–12·0) 17 22·2% (11·2–33·2) 23 11·8% (6·3–17·3) 0·005
Any recurrent cardioembolic event
1 year 2 0·5% (0·0–1·3) 0 ·· 2 1·3% (0·0–3·1) 53 14·5% (10·8–18·2) p<0·0001
5 years 14 5·1% (2·4–7·8) 4 2·3% (0·0–4·7) 3 2·2% (0·0–4·7) 74 25·0% (19·5–30·5) p<0·0001
10 years 18 9·2% (4·3–14·1) 5 4·3% (0·0–8·8) 4 6·3% (0·0–14·5) 79 31·3% (23·9–38·7) p<0·0001
p values are log-rank p, unless otherwise speciﬁ ed. mRS=modiﬁ ed Rankin Scale. *Represents absolute risk, unless otherwise speciﬁ ed. †Data missing for 22 patients: 15 for cardioembolic, three for large artery 
disease, and four for cryptogenic stroke. ‡Outcome of the index event reported as percentage of total. §χ2 test. ¶Data missing for 20 patients: ten for cardioembolic, one for large artery disease, and nine for 
cryptogenic stroke. 
Table 3: Outcome and prognosis of cryptogenic stroke and ischaemic stroke of known cause 
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Patients with cryptogenic events had a signiﬁ cantly 
lower risk of acute coronary events than did those with 
large artery disease events (adjusted HR 0·40, 95% CI 
0·24–0·66; p=0·0003) and a similar risk to those with 
non-large artery disease events (0·76, 0·49–1·18; p=0·22; 
ﬁ gure 3). Patients with cryptogenic events also had a low 
risk of presumed cardioembolic events (26 events, 10-year 
risk 6·4%, 95% CI 3·6–9·1), which was similar to that in 
patients with large artery disease and small vessel disease 
events combined (adjusted HR 1·16, 95% CI 0·62–2·17; 
p=0·64; ﬁ gure 3). No patient with cryptogenic events 
presented with any recurrent cardioembolic event within 
90 days of the index event. Of all 85 recurrent strokes of 
cryptogenic or unknown cause after an index cryptogenic 
Figure 3: 10-year absolute risks of acute coronary events, cardioembolic events, and recurrent ischaemic stroke
TIA=transient ischaemic attack. *Consisted of recurrent cardioembolic stroke, acute embolic limb ischaemia, and acute embolic visceral embolisation caused by 
presumed cardioembolism.  
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event, 82 were of a single vascular territory and three 
presented with acute infarcts in several vascular 
territories. Five peripheral vascular events with presumed 
embolic cause occurred with no proven embolic source 
after cryptogenic events versus two after small vessel 
disease and one after large artery disease events (table 4). 
The risk of any new AF during follow-up did not diﬀ er 
signiﬁ cantly between patients with cryptogenic events 
versus those with large artery disease and small vessel 
disease events combined (10-year risks 13·0% vs 9·3%; 
adjusted HR 1·23, 95% CI 0·78–1·95; p=0·37), and the 
risks of new AF-related cardioembolic events were also 
similar (5·4% vs 5·4%; 1·22, 0·60–2·50; p=0·58). The 
relative risks of cardioembolic events or new AF in 
patients with cryptogenic events versus large artery 
disease and small vessel disease events combined were 
consistent in phase 1 and phase 2 (appendix p 14). 
Sensitivity analyses excluding patients with TIA and 
comparing TOAST-deﬁ ned non-ESUS cryptogenic cases 
and ESUS cases also showed consistent results (ﬁ gure 3; 
appendix pp 15−16).
Discussion
In this population-based study, the burden of cryptogenic 
events was high, particularly in young patients. We did 
not screen for aortic atheroma, but patients with 
cryptogenic events had the lowest prevalence of risk 
factors for atherosclerosis, the lowest frequency of 
comorbid atherosclerotic disease, and the lowest risk of 
acute coronary events compared with patients with 
events of known cause. Similarly, patients with 
cryptogenic events had no excess of long-term risks of 
new AF or recurrent cardioembolic stroke or systemic 
embolism compared with large artery disease and small 
vessel disease subtypes. We did not routinely screen for 
PFO, but we found no increased prevalence of paroxysmal 
AF or minor-risk cardiac abnormalities on imaging in 
patients with cryptogenic events in phase 2 of OXVASC.
Only two previous retrospective hospital-based studies 
speciﬁ cally aimed to establish the risk-factor proﬁ le of 
cryptogenic stroke: one study of anterior circulation 
stroke15 that showed that cryptogenic stroke had similar 
prevalence of vascular risk factors to large artery disease 
and small vessel disease, and one small case-control 
study16 of patients aged younger than 60 years that showed 
that hypertension and present smoking were 
independently associated with cryptogenic stroke. 
Previous studies of prognosis of cryptogenic stroke had 
mostly only short-term follow-up, and many did not 
separate cryptogenic stroke from ischaemic stroke of 
several or unknown causes (appendix p 4). We found little 
evidence to support the suggestion that cryptogenic 
stroke might often be caused by occult arterial sources of 
thromboembolism.3 Although complex proximal aortic 
atheroma has been incorporated in the newly published 
ischaemic stroke classiﬁ cation systems,5,21 the number of 
strokes caused by such plaques remains controversial. 
Findings from case-control and hospital-based cohort 
studies showed a strong association between complex 
aortic atheroma and ischaemic stroke.22,23 However, 
population-based cohort studies have so far not conﬁ rmed 
this ﬁ nding.24–26 In studies conﬁ ned to cryptogenic stroke, 
results have also been conﬂ icting.3,27 However, the aortic 
arch is not the only potential site of occult atherosclerosis, 
and to what extent non-stenosing atherosclerosis not 
visible on lumen imaging studies might still lead to 
thromboembolism is also uncertain. We therefore used 
several potential surrogate markers of the likely overall 
burden of occult atherosclerosis: the frequency of 
traditional atherosclerotic risk factors, the prevalence of 
First recurrent ischaemic stroke Presumed PVE New AF-
related 
ischaemic 
stroke or 
PVE
Cardioembolic Large 
artery 
disease
Small 
vessel 
disease
Cryptogenic Unknown 
cause
More than 
one cause
Other 
causes
Total New 
AF
Known 
AF
No 
AF
Total
Cardioembolic 101 (89%)* 2 0 0 5 3 2 113 0 10 1 11 1
Large artery disease 4 41 (76%)* 2 1 4 0 2 54 2 0 1 3 7
Small vessel disease 4 3 37 (58%)* 15 5 0 0 64 0 0 2 2 5
Cryptogenic 17 4 5 70 (63%)* 15 1 0 112 1 0 5 6 21
Unknown cause 5 0 1 1 36 (82%)* 0 1 44 1 0 1 2 5
More than one cause 7 1 0 0 0 9 (53%)* 0 17 0 1 0 1 0
Other causes 1 0 0 0 0 1 6 (75%)* 8 0 0 1 1 0
Total 139† 51 45 87 65 14 11 412 4 11 11 26 39
Data are number of patients or number of patients with recurrent events. AF=atrial ﬁ brillation. PVE=peripheral vascular embolism. *Percentages are shown for the recurrent events that had the same cause as the 
index event. †134 (96%) were AF related. Three acute-myocardial-infarction-related recurrent strokes occurred after index cardioembolic, unknown cause, and large artery disease events, one recurrent stroke due 
to severe cardiac failure occurred after an index event of other cause, and one recurrent stroke with patent foramen ovale and concomitant pulmonary embolism occurred after an index event of unknown cause. 
Table 4: Subtypes of ﬁ rst recurrent ischaemic stroke or presumed embolic peripheral vascular events by index event subtype 
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symptomatic atherosclerosis in coronary and peripheral 
arterial territories, and the severity of any asymptomatic 
carotid stenosis. Although none of these surrogates is 
ideal, we found no evidence of any excess of atherosclerotic 
potential in patients with cryptogenic events. Findings 
from a 2012 study28 that used a similar surrogate approach 
involving genetic markers of atherosclerotic potential also 
showed a low proportion of cryptogenic strokes that were 
probably arterial in nature.28 
We also found little evidence to support the suggestion 
that cryptogenic stroke might often be caused by 
subclinical paroxysmal AF.7,8 Findings from recent studies 
of prolonged cardiac monitoring using 30-day recording 
or implantable devices have shown rates of paroxysmal AF 
of up to 16% up to 6 months after cryptogenic stroke,7,8 
with higher rates on longer-term recording.7 However, we 
do not know in how many cases these generally short runs 
of paroxysmal AF are causally related to stroke. In ASSERT 
(Asymptomatic Atrial Fibrillation and Stroke Evaluation in 
Pacemaker Patients and the Atrial Fibrillation Reduction 
Atrial Pacing Trial),29 few patients who had stroke during 
follow-up had paroxysmal AF detected on implanted 
pacemakers in the month before their event, and in many 
cases AF was detected only after an embolic event despite 
no record on prolonged monitoring beforehand. In 
phase 1 of our study, few patients with cryptogenic TIA or 
ischaemic stroke underwent ambulatory home cardiac 
monitoring, such that the rate of recurrent stroke caused 
by unrecognised paroxysmal AF in patients treated only 
with antiplatelet drugs should have been high. We found 
that the long-term risk of cardioembolic events was low 
and was no greater than after large artery disease or small 
vessel disease events. The same was true for the risk of all 
new AF on follow-up. In phase 2, when 5-day ambulatory 
cardiac monitoring was routine, the rate of paroxysmal AF 
lasting for longer than 30 s did not diﬀ er between 
otherwise cryptogenic, large artery disease, or small vessel 
disease events.
We found no excess of minor-risk cardiac abnormalities 
on echocardiography. However, since we did not screen 
routinely for PFO, we were not able to compare the 
prevalence of PFO in cryptogenic cases versus cases of 
known cause. Associations between PFO and cryptogenic 
stroke in young patients have been suggested by ﬁ ndings 
from case-control studies.3 However, the relation had 
been inconsistent in older patients.30,31 In view of evidence 
that the diameter of PFO and the prevalence of venous 
thrombosis increased with age,31 older patients might be 
more susceptible to paradoxical embolism associated 
with PFO. More research into the possible association 
between PFO and cryptogenic TIA and stroke at older 
ages is needed.
Although we consider our conclusions to be valid, our 
study has limitations. First, although intracranial 
vascular imaging was routine in phase 2 of our study, 
some patients with intracranial stenosis in phase 1 
would have been misclassiﬁ ed as having cryptogenic 
events. However, this misclassiﬁ cation should have 
biased our analysis to ﬁ nding more atherosclerotic 
markers in the cryptogenic group. Moreover, our 
analyses conﬁ ned to the cryptogenic group in phase 2 
showed results consistent with phase 1. Second, because 
brain MRI was routinely done only in phase 2, we might 
have misclassiﬁ ed some small vessel disease cases with 
non-lacunar syndrome and normal CT brain imaging as 
cryptogenic events or vice versa. However, our sensitivity 
analysis including only patients who underwent MRI 
showed consistent results. Third, echocardiography and 
prolonged ambulatory cardiac monitoring were similarly 
only done routinely in phase 2. However, we found no 
excess of paroxysmal AF or minor-risk cardiac 
abnormalities in patients with cryptogenic events in 
phase 2, suggesting that misclassiﬁ cation in phase 1 is 
unlikely to have biased our results substantially. Fourth, 
since transoesophageal echocardiography or bubble 
saline contrast echocardiography were not done in all 
patients overall, we might have underestimated the 
burden of some minor-risk cardiac abnormalities, 
although undertaking transoesophageal echo cardio-
graphy in all patients in a large population-based study 
is not feasible and is not required for the ESUS 
deﬁ nition.3 Similarly, since we did not screen routinely 
for PFO in either phase, we were not able to address the 
potential association between PFO and cryptogenic 
events. Fifth, AF was ascertained during follow-up on a 
clinical basis, and we did not repeat ambulatory 
monitoring. However, since the causative relevance of 
short runs of paroxysmal AF detected shortly after the 
index events is still debatable, the results of regular 
intensive cardiac monitoring during long-term follow-
up would be diﬃ  cult to interpret. Sixth, although we 
used several overlapping methods (ie, interviews, 
ongoing daily ascertainment, primary diagnostic coding, 
death certiﬁ cates, and national hospital coding) to 
achieve near complete follow-up, a small proportion of 
patients (<1%) who emigrated might not have been 
followed up. Finally, our results apply only to a 
predominantly white population in the UK.
Our ﬁ ndings have implications for research and 
practice. In view of the large burden of cryptogenic events 
in OXVASC and in previous population-based studies, 
further research on potential causes and treatments in 
fully investigated cohorts is needed. Future studies should 
report results separately for cryptogenic events rather 
than combining them with strokes of unknown cause 
because of incomplete investigation or those with several 
potential pathological abnormalities. More research on 
detection of aortic plaque, other non-stenosing 
atherosclerosis, intensive cardiac rhythm monitoring, 
PFO, and minor-risk cardiac abnormalities, particularly 
in the elderly, is still necessary. However, in view of the 
high rate of recurrent cryptogenic stroke, randomised 
trials of available preventive treatments, such as the 
ongoing trials of new anticoagulants,32,33 are justiﬁ ed 
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despite uncertainty about cause and might also cast light 
on the cause and pathogenesis of cryptogenic events.
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